Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Amgen’s Humira Biosimilar Gets FDA Green Light

XTALKS VITALS NEWS

Biosimilar

As well as becoming Amgen’s first biosimilar to receive regulatory approval, Amjevita has been approved for all seven indications of the reference product, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis and moderate-to-severe ulcerative colitis.

Tweetables from this article:

Tweet: Amjevita is Amgen’s first #biosimilar to receive regulatory approval http://ctt.ec/379gW+Amjevita is Amgen’s first biosimilar to receive regulatory approval.

Share this!

September 27, 2016 | by Sarah Hand, M.Sc.

In a major win for Amgen, the US Food and Drug Administration (FDA) has approved Amjevita (adalimumab-atto), a biosimilar of AbbVie’s Humira (adalimumab). As well as becoming Amgen’s first biosimilar to receive regulatory approval, Amjevita has been approved for all seven indications of the reference product, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis and moderate-to-severe ulcerative colitis.

“Approval of Amjevita is an exciting accomplishment as it marks a new chapter in Amgen's story of being a leader in biotechnology. In addition, Amjevita holds the potential to offer patients with chronic inflammatory diseases an additional treatment option,” said Dr. Sean E. Harper, executive vice president of Research and Development at Amgen. “This milestone exemplifies our ongoing dedication to the development of high quality biologic medicines.”



Both Amjevita and Humira are anti-TNF-α monoclonal antibodies. Not only does Amjevita have the same amino acid sequence as the active ingredient in Humira, but it has also been deemed highly similar to the biologic.

Amgen submitted analytical, nonclinical, pharmacokinetic and clinical data to the FDA, in order to support Amjevita’s claim of biosimilarity to adalimumab. In addition, two phase III clinical trials in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis showed the drug met its primary endpoint of equivalency to Humira.

“This is the fourth FDA-approved biosimilar,” said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research. “The biosimilar pathway is still a new frontier and one that we expect will enhance access to treatment for patients with serious medical conditions.”

As a biosimilar, Amjevita is also subject to the same FDA-mandated boxed warning as Humira. The warning alerts doctors and patients to the risks associated with the drugs’ use, including increased risk of infections, hospitalization and death. In addition, a comprehensive patient medication guide must be provided along with the drug that explains the indications and risks for both the branded biologic and the biosimilar.

Amgen is still waiting for the European Medicines Agency’s (EMA) decision on Amjevita, after applying for approval in late 2015. In all, Amgen has nine ongoing projects in its biosimilar pipeline, including the newly-approved adalimumab.


Keywords: Biosimilar, FDA, Rheumatoid Arthritis


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.